Readout Radar

185 upcoming catalysts in the next 90 days.

Every expected readout, ordered by date. Rows marked Estimate come from ClinicalTrials.gov primary-completion dates plus 6-12 weeks for database lock, data cleaning, analysis, and sponsor timing. Rows marked Guided are what management actually told the market, with sources. Click a tab to filter to one source. Dates shift; the list refreshes weekly.

Expected	Ticker	Drug	Phase	Indication	Source
Now - Sep 22, 2026	AAPG	Olverembatinib 20mg	Phase 1	Pharmacokinetic; Olverembatinib	Estimate
Now - Sep 22, 2026	APMD	Aroxybutynin and Atomoxetine	Phase 3	OSA	Estimate
Now - Sep 22, 2026	ZBIO	Obexelimab	Phase 3	Warm Autoimmune Hemolytic Anemia	Estimate
Now - Sep 23, 2026	CLYM	CLYM116	Phase 1	Healthy Volunteers	Estimate
Now - Sep 23, 2026	DWTX	Halneuron	Phase 2	Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain	Estimate Mgmt: fall of 2026 · On track
Now - Sep 23, 2026	ELVN	ELVN-002	Phase 1	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation	Estimate
Now - Sep 23, 2026	GLUE	MRT-8102	Phase 1	Healthy Volunteers; Elevated CRP	Estimate
Now - Sep 23, 2026	STTK	SL-325	Phase 1	Healthy Volunteers	Estimate
Nov 12 - Dec 24	CLDX	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria	Estimate Mgmt: September 2026 · Guide earlier than CT.gov
September 2026 Now - Sep 30, 2026	QURE	AMT-130 Phase I/II study in Huntington's disease	Phase 1/2	Huntington's disease	Guided September 2026
Now - Oct 20, 2026	LTRN	LP-184	Phase 2	Advanced Solid Tumor; Metastatic Solid Tumor; GBM	Estimate
H2 2026 Now - Dec 31, 2026	ACIU	ACI-7104 VacSYn Phase 2 in early Parkinson's disease, Part 1 week-100	Phase 2	early Parkinson's disease	Guided H2 2026
2H 2026 Now - Dec 31, 2026	ALKS	alixorexton (ALKS 2680) Vibrance-3 Phase 2 in idiopathic hypersomnia	Phase 2	idiopathic hypersomnia	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	ARVN	ARV-806 Phase 1 monotherapy dose escalation in KRAS G12D solid tumors · NCT07023731	Phase 1	KRAS G12D solid tumors	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	BBIO	infigratinib ACCEL Phase 2 program update in hypochondroplasia	Phase 2	hypochondroplasia	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	BIOA	BGE-102 Phase 2 QUELL-CV in obesity with elevated systemic inflammation and cardiovascular risk factors	Phase 2	obesity with elevated systemic inflammation and cardiovascular risk factors	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	CHRS	casdozokitug randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L unresectable HCC · NCT06679985	Phase 2	1L unresectable HCC	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	EXEL	zanzalintinib Phase 3 STELLAR-304 of zanzalintinib plus nivolumab in untreated advanced non-clear-cell RCC	Phase 3	untreated advanced non-clear-cell RCC	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	GNLX	Olvi-Vec Phase 3 OnPrime/GOG-3076 registrational trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer · NCT05281471	Phase 3	platinum-resistant/refractory ovarian cancer	Guided 2H 2026
H2 2026 Now - Dec 31, 2026	KPTI	selinexor SENTRY-2 Phase 2 (60 mg cohort, myelofibrosis) · NCT05980806	Phase 2	—	Guided H2 2026
2H 2026 Now - Dec 31, 2026	MANE	VDPHL01 confirmatory Phase 3 Study 304 in male pattern hair loss	Phase 3	male pattern hair loss	Guided 2H 2026
2H 2026 Now - Dec 31, 2026	TNGX	TNG456 Phase 1/2 of TNG456 (brain-penetrant MTAP-selective PRMT5 inhibitor) in glioblastoma and other cancers	Phase 1/2	glioblastoma and other cancers	Guided 2H 2026
September to October 2026 Now - Oct 31, 2026	ACAD	remlifanserin (formerly ACP-204) RADIANT Phase 2 in Alzheimer's disease psychosis · NCT06159673	Phase 2	Alzheimer's disease psychosis	Guided September to October 2026
Now - Oct 23, 2026	JANX	JANX008	Phase 1	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck	Estimate
Now - Oct 24, 2026	ACRS	ATI-045	Phase 2	Atopic Dermatitis; Atopic; Dermatitis	Estimate
Now - Oct 24, 2026	ANRO	ALTO-100	Phase 2	Bipolar Disorder I or II With a Major Depressive Episode	Estimate
Now - Oct 24, 2026	AVIR	Methadone	Phase 1	Healthy Volunteer Study	Estimate
Now - Oct 24, 2026	BMRN	Vosoritide	Phase 3	Hypochondroplasia	Estimate
Now - Oct 24, 2026	CRIS	Emavusertib	Phase 2	Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma	Estimate
Now - Oct 24, 2026	CYTK	Aficamten	Phase 3	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy	Estimate
Now - Oct 24, 2026	ENSC	PF614 capsule	Phase 3	Postoperative Pain, Acute	Estimate
Now - Oct 24, 2026	GRFS	Alpha-1 MP	Phase 3	Pulmonary Emphysema in Alpha-1 PI Deficiency	Estimate
Now - Oct 24, 2026	HELP	CYB003	Phase 3	Major Depressive Disorder	Estimate
Now - Oct 24, 2026	IGC	IGC-AD1-Active	Phase 2	Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden	Estimate
Now - Oct 24, 2026	IVVD	VYD2311-SD	Phase 3	COVID-19	Estimate Mgmt: Q3 2026 · On track
Now - Oct 24, 2026	KOD	Tarcocimab tedromer	Phase 3	Wet Age-related Macular Degeneration	Estimate
Now - Oct 24, 2026	MANE	VDPHL01	Phase 2	Androgenetic Alopecia; AGA; Male Pattern Baldness	Estimate
Now - Oct 24, 2026	PHVS	Deucrictibant	Phase 3	Hereditary Angioedema (HAE)	Estimate
Sep 23 - Nov 4	ACRV	ACR-2316	Phase 1	Specific Advanced Solid Tumors	Estimate
October 2026 Oct 1-31	CRVO	neflamapimod Phase 2a trial in nfvPPA · NCT07033481	Phase 2a	nfvPPA	Guided October 2026
Now - Oct 28, 2026	RAPP	RAP-219	Phase 2	Bipolar 1 Disorder	Estimate Mgmt: October 2026 · On track
Oct 6 - Nov 17	CLRB	CLR 131	Phase 1	Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor	Estimate
Oct 11 - Nov 22	GENB	GB-7624	Phase 1	Atopic Dermatitis (AD)	Estimate
Oct 11 - Nov 22	MSLE	SAT-3247	Phase 2	Duchenne Muscular Dystrophy (DMD)	Estimate Mgmt: Q4 2026 · On track
Oct 12 - Nov 23	EXEL	XL092	Phase 1	Neoplasm Malignant; Renal Cell Carcinoma; Hormone Receptor Positive Breast Carcinoma	Estimate
Oct 12 - Nov 23	NRIX	NX-1607	Phase 1	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer	Estimate
Oct 13 - Nov 24	ABVX	Obefazimod 50 mg Capsule	Phase 1	Healthy	Estimate
Oct 13 - Nov 24	ALKS	Olanzapine	Phase 3	Schizophrenia; Bipolar I Disorder	Estimate
Oct 13 - Nov 24	ARDX	Tenapanor 50 MG	Phase 3	Irritable Bowel Syndrome With Constipation (IBS-C)	Estimate
Oct 13 - Nov 24	DSGN	DT-168	Phase 2	Fuchs Endothelial Corneal Dystrophy; Fuchs	Estimate
Oct 13 - Nov 24	EWTX	Sevasemten 10 mg	Phase 2	Becker Muscular Dystrophy	Estimate
Oct 13 - Nov 24	GMAB	Epcoritamab	Phase 2	B-Cell Non-Hodgkin Lymphoma	Estimate
Oct 13 - Nov 24	GPCR	Aleniglipron	Phase 2	Obese; Obesity; Obesity Type 2 Diabetes Mellitus	Estimate
Oct 13 - Nov 24	IRON	DISC-1459	Phase 3	Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)	Estimate Mgmt (bitopertin): Q4 2026 · On track
Oct 13 - Nov 24	KPTI	Selinexor	Phase 2	Myelofibrosis	Estimate
Oct 13 - Nov 24	LNTH	Florbetaben F18	Phase 1	Cardiac Amyloidosis	Estimate
Oct 13 - Nov 24	LTGO	LTG-001	Phase 1	Healthy	Estimate
Oct 13 - Nov 24	MAZE	MZE829	Phase 2	Proteinuric Kidney Disease	Estimate
Oct 13 - Nov 24	ORIC	ORIC-114	Phase 1/2	Solid Tumors	Estimate
Oct 13 - Nov 24	PCSA	PCS6422 and capecitabine	Phase 2	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer	Estimate
Oct 13 - Nov 24	SUPN	SPN-812	Phase 3	Attention-Deficit/Hyperactivity Disorder	Estimate
Oct 13 - Nov 24	TLSA	Foralumab	Phase 2	Secondary Progressive Multiple Sclerosis	Estimate
Oct 13 - Nov 24	TNGX	TNG260	Phase 2	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer	Estimate
Oct 13 - Nov 24	VERA	Atacicept	Phase 2	IgA Nephropathy (IgAN); Berger Disease	Estimate
Oct 13 - Nov 24	VNDA	Tasimelteon	Phase 3	Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders	Estimate
Oct 13 - Nov 24	WVE	WVE-006	Phase 2	Alpha-1 Antitrypsin Deficiency	Estimate
Q4 2026 Oct 1 - Dec 31	AXSM	solriamfetol Phase 3 ENGAGE in binge-eating disorder	Phase 3	binge-eating disorder	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	AZTR	ATR-04 first cohort of Phase 1/2 in EGFR inhibitor-associated rash · NCT06830863	Phase 1/2	EGFR inhibitor-associated rash	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	CGEM	velinotamig multi-dose regimen data in SLE from Genrix China Phase 1/2a study	Phase 1/2a	SLE from Genrix China Phase 1/2a study	Guided Q4 2026
November 2026 Nov 1-30	COGT	bezuclastinib FDA decision on bezuclastinib NDA in GIST (PDUFA) and NonAdvSM (PDUFA)	PDUFA	GIST and NonAdvSM	Guided November 2026
Q4 2026 Oct 1 - Dec 31	DTIL	PBGENE-DMD Phase 1/2 FUNCTION-DMD in Duchenne muscular dystrophy	Phase 1/2	Duchenne muscular dystrophy	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	EPRX	EP-104GI RESOLVE Phase 2b in eosinophilic esophagitis (interim)	Phase 2b	eosinophilic esophagitis	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	GMAB	Rina-S Rina-S Phase 2 and Phase 3 RAINFOL datasets in platinum-resistant ovarian cancer	Phase 2	platinum-resistant ovarian cancer	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	KRYS	KB803 IOLITE registrational Phase 3 in corneal abrasions in dystrophic epidermolysis bullosa · NCT07016750	Phase 3	dystrophic epidermolysis bullosa	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	KYMR	KT-621 BROADEN2 Phase 2b in moderate to severe atopic dermatitis	Phase 2b	moderate to severe atopic dermatitis	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	NVCT	NXP900 Phase 1b of NXP900 + osimertinib in EGFR+ NSCLC	Phase 1b	EGFR+ NSCLC	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	ORKA	ORKA-001 EVERLAST-B Phase 2 of ORKA-001 in moderate-to-severe plaque psoriasis	Phase 2	moderate-to-severe plaque psoriasis	Guided Q4 2026
Q4 2026 Oct 1 - Dec 31	PRAX	relutrigine (PRAX-562) EMERALD Phase 3 registrational study in broad DEEs	Phase 3	broad DEEs	Guided Q4 2026
Oct 31 - Dec 12	TEVA	FP	Phase 3	Asthma	Estimate
Nov 2 - Dec 14	CRDL	CardiolRx	Phase 3	Recurrent Pericarditis	Estimate
Nov 3 - Dec 15	MRNA	mRNA-1403	Phase 2	Norovirus Acute Gastroenteritis	Estimate
Nov 3 - Dec 15	ONC	Sonrotoclax	Phase 2	Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory	Estimate
Nov 8 - Dec 20	BIIB	Litifilimab	Phase 3	Lupus Erythematosus, Systemic	Estimate
Nov 9 - Dec 21	MLTX	Sonelokimab	Phase 3	Hidradenitis Suppurativa	Estimate
Nov 9 - Dec 21	OCGN	OCU410ST	Phase 2/3	Stargardt Disease	Estimate
Nov 10 - Dec 22	GSK	Depemokimab	Phase 3	Eosinophilic Granulomatosis With Polyangiitis	Estimate
Nov 11 - Dec 23	ARWR	ARO-DIMERPA	Phase 2	Hyperlipidemia; Mixed	Estimate
Nov 11 - Dec 23	AZN	Durvalumab	Phase 3	Non-Small Cell Lung Cancer	Estimate
Nov 11 - Dec 23	CCCC	cemsidomide	Phase 1	Multiple Myeloma; Lymphoma, Non-Hodgkin's	Estimate
Nov 11 - Dec 23	CHRS	CHS-114	Phase 1	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma	Estimate
Nov 11 - Dec 23	CRVO	Neflamapimod	Phase 2	Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke	Estimate
Nov 11 - Dec 23	JAZZ	Zanidatamab	Phase 3	Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma	Estimate
Nov 12 - Dec 24	ABBV	Surabgene lomparvovec (RGX-314)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration	Estimate
Nov 12 - Dec 24	ABOS	sabirnetug	Phase 2	Alzheimer Disease	Estimate
Nov 12 - Dec 24	ARGX	efgartigimod PH20 SC	Phase 3	Primary Immune Thrombocytopenia	Estimate
Nov 12 - Dec 24	BHVN	BHV-7000	Phase 2/3	Focal Epilepsy	Estimate
Nov 12 - Dec 24	BNTX	BNT163	Phase 1	Genital Herpes Simplex Type 2	Estimate
Nov 12 - Dec 24	COCP	CDI-988	Phase 2	Norovirus	Estimate Mgmt: late 2026 or early 2027 · On track
Nov 12 - Dec 24	CORT	Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis	Estimate
Nov 12 - Dec 24	GILD	Sacituzumab Govitecan-hziy	Phase 2	Solid Tumor	Estimate
Nov 12 - Dec 24	HCM	HMPL-760	Phase 1	Healthy Participants	Estimate
Nov 12 - Dec 24	IBRX	N-803 (IL-15 Superagonist)	Phase 2	Long COVID	Estimate
Nov 12 - Dec 24	IDYA	IDE-161	Phase 1	Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer	Estimate
Nov 12 - Dec 24	IMVT	IMVT-1402	Phase 2	Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus	Estimate
Nov 12 - Dec 24	JBIO	JADE101	Phase 1	Healthy Volunteers	Estimate
Nov 12 - Dec 24	LLY	Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis	Estimate
Nov 12 - Dec 24	MIRM	Maralixibat	Phase 3	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)	Estimate Mgmt (LIVMARLI (maralixibat)): Q4 2026 · On track
Nov 12 - Dec 24	NVO	Ziltivekimab	Phase 3	Heart Failure; Systemic Inflammation	Estimate
Nov 12 - Dec 24	OGN	tapinarof cream, 1%	Phase 3	Plaque Psoriasis	Estimate
Nov 12 - Dec 24	PHAT	Vonoprazan	Phase 2	Eosinophilic Esophagitis	Estimate Mgmt (vonoprazan (VOQUEZNA)): Q4 2026 · On track
Nov 12 - Dec 24	RGNX	Surabgene lomparvovec (RGX-314)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration	Estimate Mgmt (RGX-314 (surabgene lomparvovec / ABBV-RGX-314)): Q4 2026 · On track
Nov 12 - Dec 24	SLGL	Patidegib Topical Gel	Phase 3	Gorlin Syndrome	Estimate
Nov 12 - Dec 24	XENE	XEN1101	Phase 3	Focal Onset Seizures	Estimate
Nov 13 - Dec 25	TAK	TAK-861	Phase 3	Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy	Estimate
Nov 16 - Dec 28	BMY	KarXT	Phase 3	Psychosis Associated With Alzheimer's Disease	Estimate
Nov 18 - Dec 30	REGN	Dupilumab	Phase 3	Atopic Dermatitis	Estimate
Nov 20, 2026 - Jan 1, 2027	INCY	Ruxolitinib Cream	Phase 3	Hidradenitis Suppurativa	Estimate Mgmt (Ruxolitinib cream (Opzelura)): Q4 2026 · On track
Nov 23, 2026 - Jan 4, 2027	JNJ	Apalutamide	Phase 3	Metastatic Castrate-sensitive Prostate Cancer	Estimate
December 2026 Dec 1-31	CRIS	Emavusertib TakeAim CLL Phase 2 of emavusertib in combination with zanubrutinib · NCT07271667	Phase 2	combination with zanubrutinib	Guided December 2026
December 2026 Dec 1-31	KOD	KSI-101 PEAK Phase 3, Pivotal Analysis 1 (first 300-patient cohort) in macular edema secondary to inflammation · NCT06990399	Phase 3	macular edema secondary to inflammation	Guided December 2026
Nov 25, 2026 - Jan 6, 2027	SNY	Itepekimab (SAR440340)	Phase 3	Chronic Rhinosinusitis With Nasal Polyps	Estimate
Dec 3, 2026 - Jan 14, 2027	AMGN	Dazodalibep	Phase 3	Sjögren's Syndrome (SS)	Estimate Mgmt: H2 2026 · On track
Dec 7, 2026 - Jan 18, 2027	NVS	Inclisiran sodium 300 mg	Phase 3	Coronary Artery Disease	Estimate
Dec 8, 2026 - Jan 19, 2027	VRTX	VX-581	Phase 1	Cystic Fibrosis	Estimate
Dec 9, 2026 - Jan 20, 2027	MRK	Belzutifan	Phase 3	Carcinoma, Renal Cell	Estimate
late 2026 or early 2027 Now - Apr 30, 2027	SEPN	SEP-479 Phase 1 single/multiple-ascending dose in healthy volunteers	Phase 1	healthy volunteers	Guided late 2026 or early 2027
Dec 11, 2026 - Jan 22, 2027	MBX	MBX 4291	Phase 1	Obesity	Estimate
Dec 11, 2026 - Jan 22, 2027	PFE	Encorafenib	Phase 3	Melanoma	Estimate
Dec 12, 2026 - Jan 23, 2027	ANNX	Vonaprument	Phase 3	Geographic Atrophy	Estimate Mgmt: Q4 2026 · On track
Dec 12, 2026 - Jan 23, 2027	OLMA	Palazestrant	Phase 3	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer	Estimate
Dec 12, 2026 - Jan 23, 2027	REPL	RP2	Phase 1	Cancer	Estimate
Dec 12, 2026 - Jan 23, 2027	RYTM	Setmelanotide	Phase 2	Prader-Willi Syndrome; Obesity; Hyperphagia	Estimate
Dec 12, 2026 - Jan 23, 2027	SRPT	Eteplirsen	Phase 3	Muscular Dystrophy, Duchenne	Estimate
Dec 12, 2026 - Jan 23, 2027	TGTX	Ublituximab	Phase 3	Relapsing Multiple Sclerosis	Estimate
Dec 13, 2026 - Jan 24, 2027	ATOS	(Z)-endoxifen	Phase 2	Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer	Estimate
Dec 13, 2026 - Jan 24, 2027	CGEM	CLN-978	Phase 1	NHL; NHL, Relapsed, Adult	Estimate
Dec 13, 2026 - Jan 24, 2027	CGON	Cretostimogene Grenadenorepvec	Phase 3	Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer	Estimate
Dec 13, 2026 - Jan 24, 2027	CRBP	CRB-601 monoclonal antibody	Phase 1/2	Solid Tumor	Estimate
Dec 13, 2026 - Jan 24, 2027	DRUG	BMB-101	Phase 2	Prader-Willi Syndrome	Estimate
Dec 13, 2026 - Jan 24, 2027	ENTA	EDP-978	Phase 1	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria	Estimate
Dec 13, 2026 - Jan 24, 2027	ERAS	ERAS-007	Phase 2	Advanced or Metastatic Solid Tumors	Estimate
Dec 13, 2026 - Jan 24, 2027	HRMY	Clemizole HCl	Phase 3	Lennox Gastaut Syndrome	Estimate
Dec 13, 2026 - Jan 24, 2027	IMUX	IMU-838 tablets	Phase 3	Multiple Sclerosis	Estimate
Dec 13, 2026 - Jan 24, 2027	KPRX	KIO-104	Phase 2	Macular Edema	Estimate Mgmt: late 2026 · On track
Dec 13, 2026 - Jan 24, 2027	KRYS	KB111	Early Phase 1	Hailey Hailey Disease; Skin Diseases; Lesion Skin	Estimate
Dec 13, 2026 - Jan 24, 2027	MGNX	MGD024	Phase 1	Leukemia, Acute Myeloid; Myelodysplastic Syndromes; Classical Hodgkin Lymphoma	Estimate
Dec 13, 2026 - Jan 24, 2027	NAMS	Obicetrapib	Phase 3	Atherosclerotic Cardiovascular Disease	Estimate Mgmt: Q1 2027 · On track
Dec 13, 2026 - Jan 24, 2027	RCUS	AB801	Phase 1	Advanced Cancer	Estimate
Dec 13, 2026 - Jan 24, 2027	SRRK	Apitegromab	Phase 3	Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2	Estimate
Dec 13, 2026 - Jan 24, 2027	TRAW	TRX-100	Phase 2	Influenza	Estimate
Dec 13, 2026 - Jan 24, 2027	TYRA	TYRA-300	Phase 2	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor	Estimate
Dec 13, 2026 - Jan 24, 2027	VIR	Tobevibart	Phase 2	Viral Hepatitis	Estimate
Dec 13, 2026 - Jan 24, 2027	ZURA	Tibulizumab Dose A	Phase 2	Hidradenitis Suppurativa (HS)	Estimate
Q1 2027 Jan 1 - Mar 31	AVIR	bemnifosbuvir + ruzasvir (BEM/RZR) Phase 3 C-FORWARD in chronic HCV, conducted outside North America · NCT07037277	Phase 3	chronic HCV	Guided Q1 2027
Q1 2027 Jan 1 - Mar 31	BMEA	icovamenib COVALENT-211 Phase II 26-week primary endpoint topline in insulin-deficient type 2 diabetes · NCT07502495	Phase 2	insulin-deficient type 2 diabetes	Guided Q1 2027
Q1 2027 Jan 1 - Mar 31	CGEN	COM701 MAIA-ovarian adaptive platform trial interim analysis, median progression-free survival data · NCT06888921	—	—	Guided Q1 2027
Q1 2027 Jan 1 - Mar 31	DMAC	DM199 Phase 2/3 ReMEDy2 in acute ischemic stroke · NCT05065216	Phase 2/3	acute ischemic stroke	Guided Q1 2027
Q1 2027 Jan 1 - Mar 31	PMN	PMN310 PRECISE-AD Phase 1b in early Alzheimer's disease	Phase 1b	early Alzheimer's disease	Guided Q1 2027
Q1 2027 Jan 1 - Mar 31	SRPT	ELEVIDYS (delandistrogene moxeparvovec-rokl) ENDEAVOR Cohort 8 - sirolimus-enhanced immunosuppression in non-ambulatory DMD; 12-week ALI/dystrophin data · NCT04626674	—	non-ambulatory DMD	Guided Q1 2027
H1 2027 Jan 1 - Jun 30	KARD	danicamtiv KINSHIP-DCM Phase 2b/3 adaptive trial in genetic dilated cardiomyopathy	—	genetic dilated cardiomyopathy	Guided H1 2027
H1 2027 Jan 1 - Jun 30	PCVX	VAX-31 OPUS-2 and OPUS-3 adult Phase 3 of VAX-31	Phase 3	—	Guided H1 2027
H1 2027 Jan 1 - Jun 30	PEPG	PGN-EDODM1 FREEDOM2-DM1 Phase 2 in DM1 (12.5 mg/kg cohort)	Phase 2	DM1	Guided H1 2027
H1 2027 Jan 1 - Jun 30	XENE	azetukalner Phase 3 X-NOVA2 of azetukalner in major depressive disorder (MDD)	Phase 3	major depressive disorder	Guided H1 2027
H1 2027 Jan 1 - Jun 30	ZNTL	azenosertib registration-intended DENALI Phase 2 of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer	Phase 2	Cyclin E1-positive platinum-resistant ovarian cancer	Guided H1 2027
Q2 2027 Apr 1 - Jun 30	MDWD	EscharEx Phase 3 VALUE trial in venous leg ulcers	Phase 3	venous leg ulcers	Guided Q2 2027
mid-2027 Apr 1 - Sep 30	ARWR	plozasiran Phase 3 YOSEMITE in HoFH	Phase 3	HoFH	Guided mid-2027
2027 Jan 1 - Dec 31	BMRN	BMN 333 registration-enabling Phase 2/3 study in achondroplasia, data update from dose-finding segment	Phase 2/3	achondroplasia	Guided 2027
2027 Jan 1 - Dec 31	DSGN	DT-168 Phase 2 biomarker trial in FECD	Phase 2	FECD	Guided 2027
2027 Jan 1 - Dec 31	ENTA	zelicapavir LOTUS Phase 2b in pediatric RSV patients	Phase 2b	pediatric RSV patients	Guided 2027
2027 Jan 1 - Dec 31	EVMN	EVO756 Phase 2b dose-ranging trial in migraine prophylaxis	Phase 2b	migraine prophylaxis	Guided 2027
2027 Jan 1 - Dec 31	IMVT	IMVT-1402 potentially registrational trials in Graves' disease and generalized myasthenia gravis	Registrational	Graves' disease and generalized myasthenia gravis	Guided 2027
2027 Jan 1 - Dec 31	JBIO	JADE101 Phase 2 JUNIPER in IgA nephropathy	Phase 2	IgA nephropathy	Guided 2027
2027 Jan 1 - Dec 31	MDGL	resmetirom (Rezdiffra) F4-C MAESTRO Outcomes study (event-driven)	—	—	Guided 2027
2027 Jan 1 - Dec 31	NBIX	osavampator (NBI-1065845) Phase 3 trials in major depressive disorder	Phase 3	major depressive disorder	Guided 2027
2027 Jan 1 - Dec 31	RVMD	daraxonrasib RASolve 301 Phase 3 in RAS-mutant NSCLC	Phase 3	RAS-mutant NSCLC	Guided 2027
Q3 2027 Jul 1 - Sep 30	BCRX	navenibart Phase 3 ALPHA-ORBIT in hereditary angioedema · NCT06842823	Phase 3	hereditary angioedema	Guided Q3 2027
Q3 2027 Jul 1 - Sep 30	STOK	zorevunersen Phase 3 EMPEROR in Dravet syndrome · NCT06872125	Phase 3	Dravet syndrome	Guided Q3 2027
2H 2027 Jul 1 - Dec 31	TVTX	pegtibatinase pivotal Phase 3 HARMONY Study in classical homocystinuria (HCU)	Phase 3	classical homocystinuria	Guided 2H 2027
2H 2027 Jul 1 - Dec 31	XNCR	XmAb942 Phase 2b XENITH-UC of XmAb942 in moderately to severely active ulcerative colitis	Phase 2b	moderately to severely active ulcerative colitis	Guided 2H 2027
late 2027 Sep 1 - Dec 31	AVLN	AP02 AURA Phase 2 in IPF	Phase 2	IPF	Guided late 2027
Q1 2028 Jan 1 - Mar 31	OCUL	OTX-TKI (AXPAXLI) SOL-R Phase 3 non-inferiority trial of AXPAXLI in wet AMD	Phase 3	wet AMD	Guided Q1 2028
2028 Jan 1 - Dec 31	KURA	ziftomenib KOMET-017 pivotal Phase 3 frontline combination in NPM1-m/KMT2A-r AML · NCT07007312	Phase 3	NPM1-m/KMT2A-r AML	Guided 2028
2H 2028 Jul 1 - Dec 31	DNTH	claseprubart Phase 3 EMERGE registrational trial in generalized myasthenia gravis	Phase 3	generalized myasthenia gravis	Guided 2H 2028
2H 2028 Jul 1 - Dec 31	GPCR	aleniglipron Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational trials in chronic weight management	Phase 3	chronic weight management	Guided 2H 2028
event-driven	SLS	galinpepimut-S (GPS) Phase 3 REGAL in AML second complete remission (CR2); event-driven final analysis at 80th death event	Phase 3	AML second complete remission	Guided event-driven

Estimates = registry primary-completion date + 6-12 weeks. Guided rows = management's own words. Sponsors report on their own schedule. Trials that already reported topline move to Recently reported.

Expected readout	Ticker	Drug	Phase	Indication
Now - Sep 22, 2026	AAPG	Olverembatinib 20mg	Phase 1	Pharmacokinetic; Olverembatinib
Now - Sep 22, 2026	APMD	Aroxybutynin and Atomoxetine	Phase 3	OSA
Now - Sep 22, 2026	ZBIO	Obexelimab	Phase 3	Warm Autoimmune Hemolytic Anemia
Now - Sep 23, 2026	CLYM	CLYM116	Phase 1	Healthy Volunteers
Now - Sep 23, 2026	DWTX	Halneuron	Phase 2	Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain
Now - Sep 23, 2026	ELVN	ELVN-002	Phase 1	HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer; HER2 Gene Mutation
Now - Sep 23, 2026	GLUE	MRT-8102	Phase 1	Healthy Volunteers; Elevated CRP
Now - Sep 23, 2026	STTK	SL-325	Phase 1	Healthy Volunteers
Now - Oct 20, 2026	LTRN	LP-184	Phase 2	Advanced Solid Tumor; Metastatic Solid Tumor; GBM
Now - Oct 23, 2026	JANX	JANX008	Phase 1	Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck
Now - Oct 24, 2026	ACRS	ATI-045	Phase 2	Atopic Dermatitis; Atopic; Dermatitis
Now - Oct 24, 2026	ANRO	ALTO-100	Phase 2	Bipolar Disorder I or II With a Major Depressive Episode
Now - Oct 24, 2026	AVIR	Methadone	Phase 1	Healthy Volunteer Study
Now - Oct 24, 2026	BMRN	Vosoritide	Phase 3	Hypochondroplasia
Now - Oct 24, 2026	CRIS	Emavusertib	Phase 2	Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma
Now - Oct 24, 2026	CYTK	Aficamten	Phase 3	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Now - Oct 24, 2026	ENSC	PF614 capsule	Phase 3	Postoperative Pain, Acute
Now - Oct 24, 2026	GRFS	Alpha-1 MP	Phase 3	Pulmonary Emphysema in Alpha-1 PI Deficiency
Now - Oct 24, 2026	HELP	CYB003	Phase 3	Major Depressive Disorder
Now - Oct 24, 2026	IGC	IGC-AD1-Active	Phase 2	Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden
Now - Oct 24, 2026	IVVD	VYD2311-SD	Phase 3	COVID-19
Now - Oct 24, 2026	KOD	Tarcocimab tedromer	Phase 3	Wet Age-related Macular Degeneration
Now - Oct 24, 2026	MANE	VDPHL01	Phase 2	Androgenetic Alopecia; AGA; Male Pattern Baldness
Now - Oct 24, 2026	PHVS	Deucrictibant	Phase 3	Hereditary Angioedema (HAE)
Now - Oct 28, 2026	RAPP	RAP-219	Phase 2	Bipolar 1 Disorder
Sep 23 - Nov 4	ACRV	ACR-2316	Phase 1	Specific Advanced Solid Tumors
Oct 6 - Nov 17	CLRB	CLR 131	Phase 1	Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor
Oct 11 - Nov 22	GENB	GB-7624	Phase 1	Atopic Dermatitis (AD)
Oct 11 - Nov 22	MSLE	SAT-3247	Phase 2	Duchenne Muscular Dystrophy (DMD)
Oct 12 - Nov 23	EXEL	XL092	Phase 1	Neoplasm Malignant; Renal Cell Carcinoma; Hormone Receptor Positive Breast Carcinoma
Oct 12 - Nov 23	NRIX	NX-1607	Phase 1	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer
Oct 13 - Nov 24	ABVX	Obefazimod 50 mg Capsule	Phase 1	Healthy
Oct 13 - Nov 24	ALKS	Olanzapine	Phase 3	Schizophrenia; Bipolar I Disorder
Oct 13 - Nov 24	ARDX	Tenapanor 50 MG	Phase 3	Irritable Bowel Syndrome With Constipation (IBS-C)
Oct 13 - Nov 24	DSGN	DT-168	Phase 2	Fuchs Endothelial Corneal Dystrophy; Fuchs
Oct 13 - Nov 24	EWTX	Sevasemten 10 mg	Phase 2	Becker Muscular Dystrophy
Oct 13 - Nov 24	GMAB	Epcoritamab	Phase 2	B-Cell Non-Hodgkin Lymphoma
Oct 13 - Nov 24	GPCR	Aleniglipron	Phase 2	Obese; Obesity; Obesity Type 2 Diabetes Mellitus
Oct 13 - Nov 24	IRON	DISC-1459	Phase 3	Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)
Oct 13 - Nov 24	KPTI	Selinexor	Phase 2	Myelofibrosis
Oct 13 - Nov 24	LNTH	Florbetaben F18	Phase 1	Cardiac Amyloidosis
Oct 13 - Nov 24	LTGO	LTG-001	Phase 1	Healthy
Oct 13 - Nov 24	MAZE	MZE829	Phase 2	Proteinuric Kidney Disease
Oct 13 - Nov 24	ORIC	ORIC-114	Phase 1/2	Solid Tumors
Oct 13 - Nov 24	PCSA	PCS6422 and capecitabine	Phase 2	Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
Oct 13 - Nov 24	SUPN	SPN-812	Phase 3	Attention-Deficit/Hyperactivity Disorder
Oct 13 - Nov 24	TLSA	Foralumab	Phase 2	Secondary Progressive Multiple Sclerosis
Oct 13 - Nov 24	TNGX	TNG260	Phase 2	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer
Oct 13 - Nov 24	VERA	Atacicept	Phase 2	IgA Nephropathy (IgAN); Berger Disease
Oct 13 - Nov 24	VNDA	Tasimelteon	Phase 3	Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders
Oct 13 - Nov 24	WVE	WVE-006	Phase 2	Alpha-1 Antitrypsin Deficiency
Oct 31 - Dec 12	TEVA	FP	Phase 3	Asthma
Nov 2 - Dec 14	CRDL	CardiolRx	Phase 3	Recurrent Pericarditis
Nov 3 - Dec 15	MRNA	mRNA-1403	Phase 2	Norovirus Acute Gastroenteritis
Nov 3 - Dec 15	ONC	Sonrotoclax	Phase 2	Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory
Nov 8 - Dec 20	BIIB	Litifilimab	Phase 3	Lupus Erythematosus, Systemic
Nov 9 - Dec 21	MLTX	Sonelokimab	Phase 3	Hidradenitis Suppurativa
Nov 9 - Dec 21	OCGN	OCU410ST	Phase 2/3	Stargardt Disease
Nov 10 - Dec 22	GSK	Depemokimab	Phase 3	Eosinophilic Granulomatosis With Polyangiitis
Nov 11 - Dec 23	ARWR	ARO-DIMERPA	Phase 2	Hyperlipidemia; Mixed
Nov 11 - Dec 23	AZN	Durvalumab	Phase 3	Non-Small Cell Lung Cancer
Nov 11 - Dec 23	CCCC	cemsidomide	Phase 1	Multiple Myeloma; Lymphoma, Non-Hodgkin's
Nov 11 - Dec 23	CHRS	CHS-114	Phase 1	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma
Nov 11 - Dec 23	CRVO	Neflamapimod	Phase 2	Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke
Nov 11 - Dec 23	JAZZ	Zanidatamab	Phase 3	Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Nov 12 - Dec 24	ABBV	Surabgene lomparvovec (RGX-314)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration
Nov 12 - Dec 24	ABOS	sabirnetug	Phase 2	Alzheimer Disease
Nov 12 - Dec 24	ARGX	efgartigimod PH20 SC	Phase 3	Primary Immune Thrombocytopenia
Nov 12 - Dec 24	BHVN	BHV-7000	Phase 2/3	Focal Epilepsy
Nov 12 - Dec 24	BNTX	BNT163	Phase 1	Genital Herpes Simplex Type 2
Nov 12 - Dec 24	CLDX	barzolvolimab	Phase 3	Chronic Spontaneous Urticaria
Nov 12 - Dec 24	COCP	CDI-988	Phase 2	Norovirus
Nov 12 - Dec 24	CORT	Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis
Nov 12 - Dec 24	GILD	Sacituzumab Govitecan-hziy	Phase 2	Solid Tumor
Nov 12 - Dec 24	HCM	HMPL-760	Phase 1	Healthy Participants
Nov 12 - Dec 24	IBRX	N-803 (IL-15 Superagonist)	Phase 2	Long COVID
Nov 12 - Dec 24	IDYA	IDE-161	Phase 1	Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer
Nov 12 - Dec 24	IMVT	IMVT-1402	Phase 2	Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus
Nov 12 - Dec 24	JBIO	JADE101	Phase 1	Healthy Volunteers
Nov 12 - Dec 24	LLY	Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis
Nov 12 - Dec 24	MIRM	Maralixibat	Phase 3	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Nov 12 - Dec 24	NVO	Ziltivekimab	Phase 3	Heart Failure; Systemic Inflammation
Nov 12 - Dec 24	OGN	tapinarof cream, 1%	Phase 3	Plaque Psoriasis
Nov 12 - Dec 24	PHAT	Vonoprazan	Phase 2	Eosinophilic Esophagitis
Nov 12 - Dec 24	RGNX	Surabgene lomparvovec (RGX-314)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration
Nov 12 - Dec 24	SLGL	Patidegib Topical Gel	Phase 3	Gorlin Syndrome
Nov 12 - Dec 24	XENE	XEN1101	Phase 3	Focal Onset Seizures
Nov 13 - Dec 25	TAK	TAK-861	Phase 3	Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy
Nov 16 - Dec 28	BMY	KarXT	Phase 3	Psychosis Associated With Alzheimer's Disease
Nov 18 - Dec 30	REGN	Dupilumab	Phase 3	Atopic Dermatitis
Nov 20, 2026 - Jan 1, 2027	INCY	Ruxolitinib Cream	Phase 3	Hidradenitis Suppurativa
Nov 23, 2026 - Jan 4, 2027	JNJ	Apalutamide	Phase 3	Metastatic Castrate-sensitive Prostate Cancer
Nov 25, 2026 - Jan 6, 2027	SNY	Itepekimab (SAR440340)	Phase 3	Chronic Rhinosinusitis With Nasal Polyps
Dec 3, 2026 - Jan 14, 2027	AMGN	Dazodalibep	Phase 3	Sjögren's Syndrome (SS)
Dec 7, 2026 - Jan 18, 2027	NVS	Inclisiran sodium 300 mg	Phase 3	Coronary Artery Disease
Dec 8, 2026 - Jan 19, 2027	VRTX	VX-581	Phase 1	Cystic Fibrosis
Dec 9, 2026 - Jan 20, 2027	MRK	Belzutifan	Phase 3	Carcinoma, Renal Cell
Dec 11, 2026 - Jan 22, 2027	MBX	MBX 4291	Phase 1	Obesity
Dec 11, 2026 - Jan 22, 2027	PFE	Encorafenib	Phase 3	Melanoma
Dec 12, 2026 - Jan 23, 2027	ANNX	Vonaprument	Phase 3	Geographic Atrophy
Dec 12, 2026 - Jan 23, 2027	OLMA	Palazestrant	Phase 3	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer
Dec 12, 2026 - Jan 23, 2027	REPL	RP2	Phase 1	Cancer
Dec 12, 2026 - Jan 23, 2027	RYTM	Setmelanotide	Phase 2	Prader-Willi Syndrome; Obesity; Hyperphagia
Dec 12, 2026 - Jan 23, 2027	SRPT	Eteplirsen	Phase 3	Muscular Dystrophy, Duchenne
Dec 12, 2026 - Jan 23, 2027	TGTX	Ublituximab	Phase 3	Relapsing Multiple Sclerosis
Dec 13, 2026 - Jan 24, 2027	ATOS	(Z)-endoxifen	Phase 2	Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer
Dec 13, 2026 - Jan 24, 2027	CGEM	CLN-978	Phase 1	NHL; NHL, Relapsed, Adult
Dec 13, 2026 - Jan 24, 2027	CGON	Cretostimogene Grenadenorepvec	Phase 3	Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer
Dec 13, 2026 - Jan 24, 2027	CRBP	CRB-601 monoclonal antibody	Phase 1/2	Solid Tumor
Dec 13, 2026 - Jan 24, 2027	DRUG	BMB-101	Phase 2	Prader-Willi Syndrome
Dec 13, 2026 - Jan 24, 2027	ENTA	EDP-978	Phase 1	Chronic Inducible Urticaria; Chronic Spontaneous Urticaria
Dec 13, 2026 - Jan 24, 2027	ERAS	ERAS-007	Phase 2	Advanced or Metastatic Solid Tumors
Dec 13, 2026 - Jan 24, 2027	HRMY	Clemizole HCl	Phase 3	Lennox Gastaut Syndrome
Dec 13, 2026 - Jan 24, 2027	IMUX	IMU-838 tablets	Phase 3	Multiple Sclerosis
Dec 13, 2026 - Jan 24, 2027	KPRX	KIO-104	Phase 2	Macular Edema
Dec 13, 2026 - Jan 24, 2027	KRYS	KB111	Early Phase 1	Hailey Hailey Disease; Skin Diseases; Lesion Skin
Dec 13, 2026 - Jan 24, 2027	MGNX	MGD024	Phase 1	Leukemia, Acute Myeloid; Myelodysplastic Syndromes; Classical Hodgkin Lymphoma
Dec 13, 2026 - Jan 24, 2027	NAMS	Obicetrapib	Phase 3	Atherosclerotic Cardiovascular Disease
Dec 13, 2026 - Jan 24, 2027	RCUS	AB801	Phase 1	Advanced Cancer
Dec 13, 2026 - Jan 24, 2027	SRRK	Apitegromab	Phase 3	Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2
Dec 13, 2026 - Jan 24, 2027	TRAW	TRX-100	Phase 2	Influenza
Dec 13, 2026 - Jan 24, 2027	TYRA	TYRA-300	Phase 2	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor
Dec 13, 2026 - Jan 24, 2027	VIR	Tobevibart	Phase 2	Viral Hepatitis
Dec 13, 2026 - Jan 24, 2027	ZURA	Tibulizumab Dose A	Phase 2	Hidradenitis Suppurativa (HS)

Expected readout = registry primary-completion date + 6-12 weeks. Sponsors report on their own schedule. Trials that already reported topline move to Recently reported.

What management actually guided, with the source linked. Signal compares the guide against the ClinicalTrials.gov-based estimate and against last week's guide.

Ticker	Drug / Trial	Management says	Source	CT.gov estimate	Signal
CLDX	barzolvolimab Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 topline in chronic spontaneous urticaria · NCT06445023	September 2026 “We are looking forward to sharing the topline results from our two Phase 3 trials of barzolvolimab in the early fall and are actively driving towards potential commercialization.”	PR · Aug 6, 2026	Nov 12 - Dec 24	Guide earlier than CT.gov
IVVD	VYD2311 DECLARATION	Q3 2026 “Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026 (prior guide was mid-2026 at initiation, shifted to late Q3 2026 at June 2026 enrollmen”	PR · Sep 1, 2026	Now - Oct 24, 2026	On track
QURE	AMT-130 Phase I/II study in Huntington's disease	September 2026 “Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026”	PR · Jul 29, 2026	—	—
ACAD	remlifanserin (formerly ACP-204) RADIANT Phase 2 in Alzheimer's disease psychosis · NCT06159673	September to October 2026 “Topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis anticipated September to October 2026”	PR · Aug 4, 2026	—	—
CRVO	neflamapimod Phase 2a trial in nfvPPA · NCT07033481	October 2026 “The presentation at the ISFTD conference will highlight initial results for two plasma biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), from ”	PR · Sep 10, 2026	—	—
RAPP	RAP-219 Phase 2 trial in bipolar mania	October 2026 “The Phase 2 trial continues to progress, with topline results expected in October 2026.”	PR · Aug 5, 2026	Now - Oct 28, 2026	On track
COGT	bezuclastinib FDA decision on bezuclastinib NDA in GIST (PDUFA) and NonAdvSM (PDUFA)	November 2026 “On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitt”	PR · Aug 10, 2026	—	—
DWTX	Halneuron HAL-CINP Phase 2b in chemotherapy-induced neuropathic pain · NCT06848348	fall of 2026 “HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.”	PR · Jul 20, 2026	Now - Sep 23, 2026	On track
ACIU	ACI-7104 VacSYn Phase 2 in early Parkinson's disease, Part 1 week-100	H2 2026 “The candidate is currently being investigated in the VacSYn Phase 2 trial, an adaptive, biomarker-based study in patients with early-stage Parkinson's disease, with final Part 1 we”	PR · Aug 11, 2026	—	—
ALKS	alixorexton (ALKS 2680) Vibrance-3 Phase 2 in idiopathic hypersomnia	2H 2026 “We are excited to continue advancing enrollment in the phase 3 Brilliance Studies and work toward completing the Vibrance-3 phase 2 study in IH later this year.”	PR · Jul 13, 2026	—	—
AMGN	Dazodalibep Two Phase 3 studies in Sjögren's disease (systemic disease activity; symptom burden)	H2 2026 “Two Phase 3 studies of dazodalibep in Sjögren's disease are underway. The first study is ongoing in patients with moderate-to-severe systemic disease activity. The second study is ”	PR · Aug 4, 2026	Dec 3, 2026 - Jan 14, 2027	On track
ANNX	vonaprument ARCHER II Phase 3 in geographic atrophy, Month 15 primary analysis	Q4 2026 “Topline results from the Month 15 primary analysis are expected in the fourth quarter of 2026.”	PR · Aug 12, 2026	Dec 12, 2026 - Jan 23, 2027	On track
ARVN	ARV-806 Phase 1 monotherapy dose escalation in KRAS G12D solid tumors · NCT07023731	2H 2026 “Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026.”	PR · Aug 4, 2026	—	—
AXSM	solriamfetol Phase 3 ENGAGE in binge-eating disorder	Q4 2026 “The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026.”	PR · Aug 10, 2026	—	—
AZTR	ATR-04 first cohort of Phase 1/2 in EGFR inhibitor-associated rash · NCT06830863	Q4 2026 “Topline data from first cohort of Phase 1/2 trial expected in Q4-2026.”	PR · Aug 12, 2026	—	—
BBIO	infigratinib ACCEL Phase 2 program update in hypochondroplasia	2H 2026 “An update of the Phase 2 program in hypochondroplasia is expected in the second half of 2026.”	PR · Aug 10, 2026	—	—
BIOA	BGE-102 Phase 2 QUELL-CV in obesity with elevated systemic inflammation and cardiovascular risk factors	2H 2026 “We have dosed the first participant in QUELL-CV, our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk, with topline data anticipated in the s”	PR · Aug 5, 2026	—	—
CGEM	velinotamig multi-dose regimen data in SLE from Genrix China Phase 1/2a study	Q4 2026 “Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase 1/2 basket study in autoimmune cytopenias to begin early 2027”	PR · Aug 6, 2026	—	—
CHRS	casdozokitug randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L unresectable HCC · NCT06679985	2H 2026 “Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected 2H 2026.”	PR · Aug 5, 2026	—	—
CRIS	Emavusertib TakeAim CLL Phase 2 of emavusertib in combination with zanubrutinib · NCT07271667	December 2026 “Today, Curis is announcing that it has achieved the previously stated goal of dosing the first five patients in the TakeAim CLL study and reaffirmed its expectation to report initi”	PR · Jul 30, 2026	—	—
DTIL	PBGENE-DMD Phase 1/2 FUNCTION-DMD in Duchenne muscular dystrophy	Q4 2026 “We are grateful to the patient, their family, and the clinical team for their commitment to advancing this important work, and we look forward to reporting initial safety data by y”	PR · Aug 24, 2026	—	—
EPRX	EP-104GI RESOLVE Phase 2b in eosinophilic esophagitis (interim)	Q4 2026 “including the Phase 2b Eosinophilic Esophagitis (EoE) trial with interim data expected to be released in Q4 highlighting key clinical and histologic endpoints”	PR · Aug 11, 2026	—	—
EXEL	zanzalintinib Phase 3 STELLAR-304 of zanzalintinib plus nivolumab in untreated advanced non-clear-cell RCC	2H 2026 “In May 2026, Exelixis announced that the company expects topline results from the STELLAR-304 trial in the second half of 2026, depending on event rates.”	PR · Aug 4, 2026	—	—
GMAB	Rina-S Rina-S Phase 2 and Phase 3 RAINFOL datasets in platinum-resistant ovarian cancer	Q4 2026 “For Rina-S, we anticipate both phase II and phase III platinum-resistant ovarian cancer datasets will be available in the fourth quarter.”	Source · Aug 6, 2026	—	—
GNLX	Olvi-Vec Phase 3 OnPrime/GOG-3076 registrational trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer · NCT05281471	2H 2026 “Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26”	PR · Aug 13, 2026	—	—
INCY	Ruxolitinib cream (Opzelura) Phase 3 TRuE-HS1 and TRuE-HS2 in mild-to-moderate hidradenitis suppurativa	Q4 2026 “Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarte”	PR · Jul 28, 2026	Nov 20, 2026 - Jan 1, 2027	On track
IRON	bitopertin Phase 3 APOLLO in erythropoietic protoporphyria	Q4 2026 “The anticipated readout of the Phase 3 APOLLO trial of bitopertin in EPP in Q4 marks a significant milestone.”	PR · Jul 30, 2026	Oct 13 - Nov 24	On track
KOD	KSI-101 PEAK Phase 3, Pivotal Analysis 1 (first 300-patient cohort) in macular edema secondary to inflammation · NCT06990399	December 2026 “We were pleased to complete this important enrollment milestone in early June, and we can now confidently plan for the topline data to be released in December 2026”	PR · Aug 6, 2026	—	—
KPRX	KIO-104 KLARITY Phase 2 in macular edema due to retinal inflammation	late 2026 “We expect to report initial clinical data in late 2026.”	PR · Aug 7, 2026	Dec 13, 2026 - Jan 24, 2027	On track
KPTI	selinexor SENTRY-2 Phase 2 (60 mg cohort, myelofibrosis) · NCT05980806	H2 2026 “Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026.”	PR · Aug 13, 2026	—	—
KRYS	KB803 IOLITE registrational Phase 3 in corneal abrasions in dystrophic epidermolysis bullosa · NCT07016750	Q4 2026 “The Company's registrational, intra-patient, double-blind, de-centralized, placebo-controlled study (IOLITE) with crossover design evaluating KB803 for the treatment and prevention”	PR · Aug 3, 2026	—	—
KYMR	KT-621 BROADEN2 Phase 2b in moderate to severe atopic dermatitis	Q4 2026 “With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent rea”	PR · Jun 25, 2026	—	—
MANE	VDPHL01 confirmatory Phase 3 Study 304 in male pattern hair loss	2H 2026 “Topline data from Study '304', a confirmatory Phase 3 trial evaluating the safety and efficacy of VDPHL01 in the treatment of male pattern hair loss, are expected in the second hal”	PR · Aug 11, 2026	—	—
MIRM	LIVMARLI (maralixibat) Phase 3 EXPAND study in cholestatic pruritus due to additional rare cholestatic conditions	Q4 2026 “LIVMARLI EXPAND Phase 3 study in cholestatic pruritus due to additional rare cholestatic conditions topline results expected in Q4 2026.”	PR · Aug 5, 2026	Nov 12 - Dec 24	On track
MSLE	SAT-3247 BASECAMP (SAT-3247-CL-201)	Q4 2026 “We expect to release clinical data from the BASECAMP pediatric trial in the fourth quarter, which will help to inform our continued development and regulatory strategies.”	PR · Aug 13, 2026	Oct 11 - Nov 22	On track
NVCT	NXP900 Phase 1b of NXP900 + osimertinib in EGFR+ NSCLC	Q4 2026 “the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, ”	PR · Aug 4, 2026	—	—
ORKA	ORKA-001 EVERLAST-B Phase 2 of ORKA-001 in moderate-to-severe plaque psoriasis	Q4 2026 “EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026”	PR · Aug 10, 2026	—	—
PHAT	vonoprazan (VOQUEZNA) pHalcon-EoE-201 Phase 2 in eosinophilic esophagitis · NCT06851559	Q4 2026 “Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026.”	PR · Jun 23, 2026	Nov 12 - Dec 24	On track
PRAX	relutrigine (PRAX-562) EMERALD Phase 3 registrational study in broad DEEs	Q4 2026 “Looking ahead, we expect topline results from the POWER1 study of vormatrigine in focal epilepsy this quarter, followed by the EMERALD readout in broad DEEs in the fourth quarter.”	PR · May 7, 2026	—	—
RGNX	RGX-314 (surabgene lomparvovec / ABBV-RGX-314) ATMOSPHERE and ASCENT pivotal trials in wet AMD (subretinal delivery)	Q4 2026 “Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE and ASCENT, expected in Q4 2026.”	PR · Aug 6, 2026	Nov 12 - Dec 24	On track
TNGX	TNG456 Phase 1/2 of TNG456 (brain-penetrant MTAP-selective PRMT5 inhibitor) in glioblastoma and other cancers	2H 2026 “Release initial TNG456 data in glioblastoma and other cancers in 2H 2026”	PR · Aug 11, 2026	—	—
AVIR	bemnifosbuvir + ruzasvir (BEM/RZR) Phase 3 C-FORWARD in chronic HCV, conducted outside North America · NCT07037277	Q1 2027 “Topline results are expected in early Q1 2027 and will provide additional efficacy data across a broader range of HCV genotypes more commonly found outside of the US and Canada.”	PR · Aug 12, 2026	—	—
BMEA	icovamenib COVALENT-211 Phase II 26-week primary endpoint topline in insulin-deficient type 2 diabetes · NCT07502495	Q1 2027 “With COVALENT-211 now fully enrolled and our Phase II trial COVALENT-212 expected to complete enrollment over the coming months before year end, we remain focused on execution as w”	PR · Aug 24, 2026	—	—
CGEN	COM701 MAIA-ovarian adaptive platform trial interim analysis, median progression-free survival data · NCT06888921	Q1 2027 “Our MAIA-ovarian trial in platinum-sensitive ovarian cancer remains on track for the interim analysis with median progression-free survival data expected by the first quarter of 20”	PR · Aug 3, 2026	—	—
DMAC	DM199 Phase 2/3 ReMEDy2 in acute ischemic stroke · NCT05065216	Q1 2027 “Enrollment in the Company's Phase 2/3 ReMEDy2 (the ReMEDy2 trial - NCT05065216) trial has surpassed 85% of the 200 participants required to trigger the prespecified interim analysi”	PR · Aug 10, 2026	—	—
NAMS	obicetrapib Phase 3 PREVAIL cardiovascular outcomes trial	Q1 2027 “PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027”	PR · Aug 5, 2026	Dec 13, 2026 - Jan 24, 2027	On track
PMN	PMN310 PRECISE-AD Phase 1b in early Alzheimer's disease	Q1 2027 “The trial remains blinded and ongoing with topline 12-month results expected in the first quarter of 2027.”	PR · Jul 28, 2026	—	—
SRPT	ELEVIDYS (delandistrogene moxeparvovec-rokl) ENDEAVOR Cohort 8 - sirolimus-enhanced immunosuppression in non-ambulatory DMD; 12-week ALI/dystrophin data · NCT04626674	Q1 2027 “When we looked at the timing of when we would have the 12-week data, it would be available in Q1 of next year. When we have the complete 12-week data from the 25 patients, that'll ”	Source · Aug 5, 2026	—	—
COCP	CDI-988 Phase 1b norovirus challenge study (prevention + treatment) · NCT07198139	late 2026 or early 2027 “We look forward to reporting preliminary results near the end of 2026 or early 2027 and to advancing CDI-988 as a potential first-in-class oral antiviral for norovirus.”	PR · Sep 9, 2026	Nov 12 - Dec 24	On track
SEPN	SEP-479 Phase 1 single/multiple-ascending dose in healthy volunteers	late 2026 or early 2027 “SEP-479 is currently being evaluated in an ongoing Phase 1 single-ascending dose and multiple-ascending dose study in healthy volunteers, with data expected in late 2026 or early 2”	PR · Jun 8, 2026	—	—
KARD	danicamtiv KINSHIP-DCM Phase 2b/3 adaptive trial in genetic dilated cardiomyopathy	H1 2027 “Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027”	PR · Aug 11, 2026	—	—
MDWD	EscharEx Phase 3 VALUE trial in venous leg ulcers	Q2 2027 “Our plan is to have the interim assessment by the end of Q1. If everything goes well, it takes another quarter or so to get the top-line data. After the top-line data, it is anothe”	Source · Aug 13, 2026	—	—
PCVX	VAX-31 OPUS-2 and OPUS-3 adult Phase 3 of VAX-31	H1 2027 “OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027”	PR · Aug 5, 2026	—	—
PEPG	PGN-EDODM1 FREEDOM2-DM1 Phase 2 in DM1 (12.5 mg/kg cohort)	H1 2027 “– Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 –”	PR · Aug 6, 2026	—	—
XENE	azetukalner Phase 3 X-NOVA2 of azetukalner in major depressive disorder (MDD)	H1 2027 “We also remain focused on broadening azetukalner's opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027.”	PR · Aug 6, 2026	—	—
ZNTL	azenosertib registration-intended DENALI Phase 2 of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer	H1 2027 “We expect to provide the topline readout of DENALI Part 2 in 1H 2027.”	PR · Aug 6, 2026	—	—
ARWR	plozasiran Phase 3 YOSEMITE in HoFH	mid-2027 “The Company anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter”	PR · Aug 4, 2026	—	—
BCRX	navenibart Phase 3 ALPHA-ORBIT in hereditary angioedema · NCT06842823	Q3 2027 “The program remains on track to report top-line results from both doses in Q3 2027.”	PR · Aug 5, 2026	—	—
STOK	zorevunersen Phase 3 EMPEROR in Dravet syndrome · NCT06872125	Q3 2027 “Stoke completed enrollment in the United States, United Kingdom and Japan in June 2026, and a data readout is anticipated in the third quarter of 2027 to support the submission of ”	PR · Sep 3, 2026	—	—
AVLN	AP02 AURA Phase 2 in IPF	late 2027 “The 12-week study is designed to enroll 160 patients to assess safety and efficacy, as measured by FVC, with topline data anticipated in late 2027.”	PR · Jun 3, 2026	—	—
BMRN	BMN 333 registration-enabling Phase 2/3 study in achondroplasia, data update from dose-finding segment	2027 “The Phase 2/3 study is enrolling, with a data update expected in 2027.”	PR · Aug 6, 2026	—	—
DSGN	DT-168 Phase 2 biomarker trial in FECD	2027 “Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers, moved from prior 2H 2026 guidance.”	PR · Aug 3, 2026	—	—
ENTA	zelicapavir LOTUS Phase 2b in pediatric RSV patients	2027 “Dosing began in LOTUS, our Phase 2b trial of zelicapavir in pediatric patients with RSV in Thailand, with topline data anticipated in 2027.”	PR · Aug 10, 2026	—	—
EVMN	EVO756 Phase 2b dose-ranging trial in migraine prophylaxis	2027 “Top-line data from the trial are expected in 2027.”	PR · Aug 6, 2026	—	—
IMVT	IMVT-1402 potentially registrational trials in Graves' disease and generalized myasthenia gravis	2027 “In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG.”	PR · Aug 6, 2026	—	—
JBIO	JADE101 Phase 2 JUNIPER in IgA nephropathy	2027 “Phase 2 clinical trial in patients with IgA nephropathy underway, with interim clinical data expected in 2027”	PR · Jun 1, 2026	—	—
MDGL	resmetirom (Rezdiffra) F4-C MAESTRO Outcomes study (event-driven)	2027 “First, our F4-C MAESTRO Outcomes study, which is an event-driven trial that we expect to read out in 2027.”	Source · Jul 30, 2026	—	—
NBIX	osavampator (NBI-1065845) Phase 3 trials in major depressive disorder	2027 “With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we are building an en”	PR · Jul 30, 2026	—	—
RVMD	daraxonrasib RASolve 301 Phase 3 in RAS-mutant NSCLC	2027 “In lung cancer, we expect to complete enrollment in RASolve 301 this year, supporting an initial readout in 2027.”	Source · Aug 12, 2026	—	—
TVTX	pegtibatinase pivotal Phase 3 HARMONY Study in classical homocystinuria (HCU)	2H 2027 “The Company is continuing to enroll new patients in the pivotal Phase 3 HARMONY Study, with topline data anticipated in 2H 2027.”	PR · Aug 4, 2026	—	—
XNCR	XmAb942 Phase 2b XENITH-UC of XmAb942 in moderately to severely active ulcerative colitis	2H 2027 “We expect to complete a blinded interim analysis around year-end 2026 and complete the primary endpoint analysis for the study's 12-week induction period during the second half of ”	PR · May 6, 2026	—	—
OCUL	OTX-TKI (AXPAXLI) SOL-R Phase 3 non-inferiority trial of AXPAXLI in wet AMD	Q1 2028 “Topline data for SOL-R are now expected during the first quarter of 2028.”	PR · Jun 17, 2026	—	—
DNTH	claseprubart Phase 3 EMERGE registrational trial in generalized myasthenia gravis	2H 2028 “Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June '26, with top-line results anticipated in 2H'28”	PR · Aug 4, 2026	—	—
GPCR	aleniglipron Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational trials in chronic weight management	2H 2028 “We expect topline data in the second half of 2028.”	PR · Sep 8, 2026	—	—
KURA	ziftomenib KOMET-017 pivotal Phase 3 frontline combination in NPM1-m/KMT2A-r AML · NCT07007312	2028 “Combined with $180 million in anticipated collaboration payments from Kyowa Kirin, the Company believes its current cash resources will be sufficient to fund the ziftomenib AML pro”	PR · Aug 12, 2026	—	—
SLS	galinpepimut-S (GPS) Phase 3 REGAL in AML second complete remission (CR2); event-driven final analysis at 80th death event	event-driven “For GPS, we are approaching the pre-specified 80th event in the Phase 3 REGAL trial marking a critical step toward the final efficacy analysis and, if successful, a potential BLA s”	PR · Aug 11, 2026	—	—

Topline already out. Removed from the expected list; kept here for 90 days so you can see what just printed.

Reported	Ticker	Drug	Phase	Indication	Outcome	Headline
Sep 16, 2026	LGVN	laromestrocel (Lomecel-B) ELPIS II · NCT04925024	Phase 2b	hypoplastic left heart syndrome (HLHS)	Miss	ELPIS II missed primary (RVEF change at Month 12; LS mean diff -0.7pp, p=0.8336); exploratory MACE ~31% fewer (n.s.); cost containment + strategic-options review PR
Sep 15, 2026	CNTB	rademikibart Seabreeze STAT (asthma) · NCT06940141	Phase 2	acute exacerbations of asthma with type 2 inflammation	Mixed	66% fewer treatment failures at 28 days (not significant); significant rapid FEV1 improvement within one week PR
Sep 15, 2026	BIVI	bezisterim ADDRESS-LC · NCT06847191	Phase 2	neurological symptoms associated with Long COVID	Mixed	21 of 22 endpoints trended favoring drug; significant in high-burden subgroups; safety similar to placebo PR
Sep 14, 2026	DFTX	DT120 Panorama (MM120-301) · NCT06809595	Phase 3	Generalized Anxiety Disorder	Positive	HAM-A -5.1 placebo-adjusted at Week 12 (p<0.0001, d=0.64); pre-NDA 4Q26, NDA 1H27 PR
Sep 14, 2026	BNTX	gotistobart (BNT316/ONC-392) PRESERVE-003 · NCT05671510	Phase 3	squamous non-small cell lung cancer progressed on prior immunotherapy and chemotherapy	Positive	Stage 1: statistically significant OS benefit, nearly doubling survival vs chemo; presented at WCLC 2026 PR
Sep 14, 2026	CTNM	JNJ-5120/PIPE-307 MOONLIGHT-1 · NCT06785012	Phase 2	major depressive disorder	Negative	Missed primary MADRS improvement at Day 5 vs placebo; well tolerated PR
Sep 8, 2026	EVMN	EVO756 EVO756 AD Ph2b · NCT07150845	Phase 2b	Alzheimer's disease	Miss	Missed primary endpoint at all doses (n=121); EVO756 discontinued in AD; migraine Ph2b continues with topline 2027
Sep 4, 2026	NVS	pelacarsen Lp(a)HORIZON · NCT04023552	Phase 3	established cardiovascular disease with elevated lipoprotein(a)	Negative	Missed primary 4-point CV-event endpoint in 8,323 patients despite lower Lp(a) PR
Sep 2, 2026	RARE	apazunersen Aspire · NCT06617429	Phase 3	Angelman syndrome	Negative	Missed Bayley-4 cognitive primary and MDRI key secondary PR
Sep 2, 2026	TEVA	TEV-408 TEV-408 Phase 2a · NCT06807463	Phase 2	celiac disease	Positive	Vh:Cd ratio change -0.43 vs -0.88 at Week 8 (difference 0.45, p<0.05) PR
Sep 1, 2026	NVS	remibrutinib REMODEL-1/-2 · NCT05147220	Phase 3	relapsing multiple sclerosis	Positive	Cut annualized relapse rate and brain lesions vs teriflunomide; no liver safety signal PR
Sep 1, 2026	NVS	remibrutinib REMODEL-2 · NCT05156281	Phase 3	relapsing multiple sclerosis	Positive	REMODEL-2: cut annualized relapse rate and brain lesions vs teriflunomide; no liver safety signal PR
Aug 28, 2026	BNTX	autogene cevumeran (BNT122) BNT122-01 · NCT04486378	Phase 2	ctDNA-positive resected high-risk stage II/III colorectal cancer	Negative	Terminated after futility boundary crossed; DSMB found numerical OS imbalance PR
Aug 27, 2026	AMGN	TEZSPIRE (tezepelumab-ekko) CROSSING · NCT05583227	Phase 3	eosinophilic esophagitis	Positive	Met both co-primaries (histologic remission, dysphagia) and all key secondaries through week 52 PR
Aug 25, 2026	SYRE	SPY072 SKYWAY (RA sub-study) · NCT07148414	Phase 2	rheumatoid arthritis	Mixed	Low dose cut DAS28-CRP 1.9 vs 1.3 placebo (significant); missed internal bar, RA monotherapy deprioritized PR
Aug 19, 2026	MRK	intismeran autogene (V940) plus pembrolizumab INTerpath-001 · NCT05933577	Phase 3	completely resected stage IIB-IV melanoma (adjuvant)	Positive	Met primary RFS and key secondary DMFS vs pembrolizumab alone (magnitudes undisclosed) PR
Aug 18, 2026	AMLX	avexitide LUCIDITY · NCT06747468	Phase 3	post-bariatric hypoglycemia	Positive	55% reduction in composite Level 2/3 hypoglycemic events (p=0.000003); all secondaries met PR
Aug 17, 2026	EYPT	DURAVYU (vorolanib intravitreal insert) LUGANO · NCT06668064	Phase 3	wet age-related macular degeneration	Negative	Missed noninferiority on BCVA vs aflibercept in full dataset; stock fell ~67% PR
Aug 12, 2026	DFTX	DT120 Voyage · NCT06741228	Phase 3	Generalized Anxiety Disorder	Positive	HAM-A -5.4 placebo-adjusted at Week 12 (p<.0001) PR
Aug 12, 2026	CGEM	zipalertinib plus chemotherapy REZILIENT3 · NCT05973773	Phase 3	first-line EGFR exon 20 insertion mutation non-small cell lung cancer	Positive	Met primary PFS at planned interim analysis; IDMC recommended unblinding (HR 0.50, p=0.00015) PR
Aug 12, 2026	NTHI	NEO100 (intranasal perillyl alcohol) NEO100-01 · NCT02704858	Phase 2	recurrent IDH1-mutant high-grade glioma	Positive	6-month PFS 48.9% vs 20% benchmark (p=0.0047); median OS 26.09 months PR
Aug 10, 2026	TENX	TNX-103 (oral levosimendan) LEVEL · NCT05983250	Phase 3	pulmonary hypertension with heart failure with preserved ejection fraction	Negative	6MWD +14.0m vs +10.4m placebo (ns); missed KCCQ-TSS; NT-proBNP fell 49% more than placebo PR
Aug 10, 2026	ABCL	ABCL635 ABCL635 Phase 2 · NCT07118891	Phase 1/2	moderate-to-severe vasomotor symptoms due to menopause	Positive	Week-4 hot-flash frequency -83% vs -33% placebo (p<0.001); severity -1.4 vs -0.3 (p<0.001) PR
Aug 10, 2026	SLN	divesiran (SLN124) SANRECO · NCT05499013	Phase 2	polycythemia vera	Positive	SANRECO: 88% responders vs 19% placebo (placebo-adjusted 69%, p<0.0001); responder = no phlebotomy + HCT <45% weeks 18-36 PR
Aug 6, 2026	BIVI	bezisterim SUNRISE-PD · NCT06757010	Phase 2	early Parkinson's disease	Positive	EPNIC-15 improved -0.04 vs +0.18 placebo (d=-0.94, p=0.0006); significant on MDS-UPDRS I, II and III (n=57, 12 weeks) PR
Jul 30, 2026	KPTI	selinexor XPORT-EC-042 · NCT05611931	Phase 3	TP53 wild-type advanced/recurrent endometrial cancer (maintenance)	Negative	Missed primary PFS: mPFS 12.75 vs 7.43 mo (HR 0.76, one-sided p=0.0791); 5.3-mo gain called clinically meaningful; endometrial investment deprioritized PR
Jul 23, 2026	LLY	retatrutide TRIUMPH-2 · NCT05929079	Phase 3	obesity/overweight with type 2 diabetes	Positive	Week-80 weight loss 12.7%/19.1%/20.8% (4/9/12mg) vs 4.0% placebo; A1C down up to 1.6% PR
Jul 23, 2026	LLY	retatrutide TRIUMPH-3 · NCT05882045	Phase 3	severe obesity with established cardiovascular disease	Positive	Week-80 weight loss 21.6%/22.6% (9/12mg) vs 3.2% placebo; MACE analyses inconclusive PR
Jul 13, 2026	QTTB	bempikibart SIGNAL-AA Part B · NCT06018428	Phase 2	severe to very severe alopecia areata	Positive	35.3% mean SALT reduction at Week 36; 40% hit SALT-20; registration-directed program planned H1 2027 PR
Jul 10, 2026	TAK	TAK-861 TAK-861 Phase 2 NT1 · NCT05687972	Phase 2	narcolepsy type 1	Positive	Significant improvements in excessive daytime sleepiness and cataplexy; Phase 3 plans pending PR
Jul 8, 2026	BIIB	SAGE-324 KINETIC 2 · NCT06307961	Phase 2	essential tremor	Negative	Failed primary TETRAS upper-limb tremor endpoint; development discontinued in essential tremor PR
Jul 7, 2026	CMPS	COMP360 (psilocybin) COMP006 Part B · NCT05711940	Phase 3	treatment-resistant depression	Positive	39% of 25mg arm held 25%+ MADRS reduction through Week 26 after two fixed doses; rapid and durable profile PR
Jul 1, 2026	REGN	itepekimab Odyssey · NCT04701983	Phase 2/3	chronic obstructive pulmonary disease	Negative	Missed primary and key secondary endpoints in former smokers; COPD development discontinued PR
Jul 1, 2026	GILD	anitocabtagene autoleucel (anito-cel) iMMagine-1 · NCT05396885	Phase 2	relapsed/refractory multiple myeloma	Positive	Positive topline: strong response rates with manageable safety for BCMA CAR T PR
Jun 30, 2026	AMGN	sibeprenlimab VISIONARY · NCT05248646	Phase 3	IgA nephropathy	Mixed	Met primary proteinuria endpoint but missed key secondary eGFR endpoint; discussing with regulators PR
Jun 29, 2026	GMAB	epcoritamab plus lenalidomide EPCORE DLBCL-4 · NCT06508658	Phase 3	relapsed/refractory diffuse large B-cell lymphoma	Positive	Cut risk of progression or death 60% vs R-GemOx (HR 0.40, 95% CI 0.30-0.55, p<0.0001) PR
Jun 24, 2026	GSK	azetukalner (XEN1101) X-NOVA · NCT05712165	Phase 2	major depressive disorder	Positive	Met primary MADRS endpoint at Week 6 across all three doses (p<0.01) with dose-response trend PR